Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced in a news release that a buyer, Industrias Melder in Mexico, increased the volume of its OxC-beta Livestock order first placed in March to 2 tons from 300 kilograms.
This is significant for two reasons. One, it is Avivagen's first sale of the product in Mexico. Two, it represents the first application of OxC-beta in the dairy sector, thereby commercially validating the product.
Industrias Melder's upsized order follows positive results of two animal tests done by one of its dairy farm customers. In the first test, some of the farm's best milk producing cows were given OxC-beta Livestock and after 42 days, their health and productivity and the quality of their milk were assessed.
The results showed improvement in the quantity and quality of the milk the test cows produced. The farm's bulk tank milk's somatic cell count, a standard indicator of milk quality, dropped 54%. Milk with lower somatic cell counts often garners farms financial incentives or premiums. The lower somatic cell count also indicated improved health of the cows from which the tested milk came. In fact, the farm was financially rewarded by a global diary processor for the improvements in milk yield, quality and reduced bacterial levels it showed.
The same dairy farm conducted a second test but on a group of cows with chronic health, productivity and milk quality production problems. The results were improved cow health and milk quality. The bulk tank milk's somatic cell count decreased 67%. The number of animals deemed healthy by their veterinarian increased 8%.
"The successful outcome of these latest tests in Mexico is consistent with earlier dairy trials in New Zealand and China and provides yet further evidence of OxC-beta's benefits for dairy cattle, in addition to swine, poultry, companion animals and humans," the release noted.
Kym Anthony, CEO of Avivagen, stated, "We are very excited to announce this increase in the initial sale of OxC-beta™ Livestock to Industrias Melder and we are working to further formalize a long-term relationship with them. This sale has a twofold significance. First, it represents a critical step in bringing OxC-beta™ Livestock to Mexico, a market with annual feed sales of more than 36 million tonnes. Second, this is the first application of OxC-beta in the dairy sector and therefore it provides crucial commercial validation of the product that other customers will look to when making purchasing decisions."
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
